Syn-Ake

Functions
Botox-like
Smoothing
Antioxidant
FDA UNII
38H206R00R
INCI name
Dipeptide Diaminobutyroyl Benzylamide Diacetate

Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a cutting-edge wrinkle treatment, thanks to a remodeled synthetic tripeptide, derived initially from snake (Temple Viper) venom, Waglerin-1. Mimicking the effect of Waglerin-1, this peptide relaxes muscle movement by temporarily immobilizing facial contractions that cause facial lines and wrinkles.

It reduces muscle contractions by up to 80% (in vitro results) due to the disabling of the muscular nACh receptors. Moreover, due to the reduction in micro-contractions, a significant smoothing effect can already be noticed after 28 days, accompanied by a considerable decrease in skin wrinkles, all without altering the natural radiance of the face in the process.

A recent study demonstrated that Dipeptide Diaminobutyroyl Benzylamide Diacetate exhibits noticeable antioxidant activity in a dose-dependent manner, as confirmed by DPPH free radical tests.

Syn-Ake works to relax fine lines and wrinkles, quickly and dramatically lifting sagging skin. In addition, the enhanced tri-peptide helps diminish the appearance of expression lines, firming the skin around the eyes, forehead, and mouth for a more youthful appearance. It is recommended for use in skincare, including facial moisturizers, cleansers, anti-aging serums, and creams.
Synonyms
Waglerin-1 derived peptide
Synake

F.A.Q.

Is SYN®-AKE a competitive alternative to Botox® injections?

Invasive treatments, such as Botox injections and collagen fillers, are used to reverse the aging appearance temporarily. However, these treatments are expensive, unpleasant, and anyone who has ever flipped through a woman's glossy magazine can attest that some results are far from ideal.

SYN®-AKE is an innovative, non-invasive (needle-free) wrinkle treatment with a Botox-like effect that can help your complexion return to a younger, more natural, and relaxed state.

Changed

References

Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors
Author(s):
, , , , ,
PMID:
11724791
DOI:
10.1074/jbc.M109232200
Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests
Author(s):
, ,
PMID:
37349941
DOI:
10.1080/07391102.2023.2223681